Formulation, pharmacokinetics and pharmacodynamics of topical microbicides

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 26, Issue 4, 2012, Pages 451-462

  Adams, Jessica L ^a   Kashuba, Angela D M ^a  

^a University of North Carolina   (United States)

Author keywords

film; gel; microbicide; pharmacodynamics; pharmacokinetics; pre exposure prophylaxis; ring

Indexed keywords

CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; DAPIVIRINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MARAVIROC; MICROBICIDE; NONOXINOL 9; PLACEBO; PRO 2000; RC 101; SAVVY; TENOFOVIR; UNCLASSIFIED DRUG; VIVAGEL;

APPLICATION SITE IRRITATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLPOSCOPY; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TABLET; VAGINA MUCOSA; VAGINA RING; VAGINITIS;

EID: 84862850435     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2012.01.004     Document Type: Article

References (70)

1. *Garg S, Goldman D, Krumme M et al. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res 2010; 885: S19-S29.
2. *Malcolm RK, Edwards KL, Kiser P et al. Advances in microbicide vaginal rings. Antiviral Res 2010; 885: S30-S39.
3. Morris GC & Lacey Charles JN. Microbicides and HIV prevention: lessons from the past, looking to the future. Curr Opin Infect Dis 2010; 23: 57-63.
4. Van Damme L, Ramjee G, Alary M et al. COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial. Lancet 2002; 360: 971-977. (Pubitemid 35284107)
5. Van Damme L, Govinden R, Mirembe FM et al. Lack of effectiveness of cellulose sulfate gel for prevention of HIV transmission. N Engl J Med 2008; 359: 463-472.
6. Feldblum PJ, Adeiga A, Bakare R et al. Savvy vaginal gtel (C13G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008; 3: e1474.
7. Hillier SL, Moench T, Shattock R et al. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr 2005; 39: 1-8. (Pubitemid 40617012)
8. Fichorova RN, Tucker LD & Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2009; 200: 599-608.
9. Gupta K, Hillier SL, Hooton TM et al. Effects of contraceptive method on the vaginal microbial flora: a prospective evaluation. J Infect Dis 2000; 181: 595-601. (Pubitemid 30131827)
10. Anderson RA, Feathergill KA, Diao XH et al. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl 2002; 23: 426-438. (Pubitemid 34297332)
11. Mauck C, Weiner DH, Ballagh S et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study. Contraception 2001; 64: 383-391. (Pubitemid 34143209)
12. Doh AS, Ngoh N, Roddy R et al. Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days. Contraception 2007; 76: 245-249. (Pubitemid 47247661)
13. Malonza IM, Mirembe F, Nakabiito C et al. Expanded phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS 2005; 19: 2157-2163. (Pubitemid 41669005)
14. El-Sadr WM, Mayer KH, Maslankowski L et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS 2006; 20: 1109-1116. (Pubitemid 43786098)
15. *Pirrone V, Wigdahl B & Krebs FC. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res 2011; 90: 168-182.
16. Schwartz JL, Mauck C, Lai JJ et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized, double-blind, Phase 1 safety study. Contraception 2006; 74: 133-140. (Pubitemid 44062469)
17. Bax R, Douville K, McCormick D et al. Microbicides-evaluating multiple formulations of C31G. Contraception 2002; 66: 365-368.
18. Krebs FC, Miller SR, Catalone BJ et al. Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes. Antimicrob Agents Chemother 2000; 44: 1954-1960. (Pubitemid 30422954)
19. Mauck CK, Weiner DH, Creinin MD et al. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra strength gynol II. Contraception 2004; 70: 233-240. (Pubitemid 39119986)
20. Mauck CK, Creinin MD, Barnhart KT et al. A Phase I comparative postcoital testing study of three concentrations of C31G. Contraception 2004; 70: 227-231. (Pubitemid 39119985)
21. Ballagh SA, Baker JM, Henry DM et al. Safety of single daily use for one week of C31G HEC gel in women. Contraception 2002; 66: 369-375. (Pubitemid 35346611)
22. Peterson L, Nanda K, Opoku BK et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3 double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007; 2: e1312.
23. McGowan I, Gomez K, Bruder K et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS 2011; 25: 1057-1064.
24. Moscicki AB, Kaul R, Yifei et al. Measurement of muscosal biomarkers in a phase 1 trial of intravaginal 3% SPL 7013 (VivaGel®) to assess expanded safety. J Acquir Immune Defic Syndr 2011. epub ahead of print.
25. Starpharma Holdings Limited. Vivagel® [homepage on the Internet]. Victoria, Australia 2011, http://www.starpharma.com/vivagel [accessed 15.01.12].
26. Abdool Karim SS, Richardson BA, Ramjee G et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011; 25: 957-966.
27. McCormack S, Ramjee G, Kamali A et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomized, double-blind, parallel-group trial. Lancet 2010; 376: 1329-1337.
28. Skoler-Karpoff S, Ramjee G, Ahmed K et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1977-1987.
29. Olmsted SS, Dubin NH, Cone RA et al. The rates at which human sperm are immobilized and killed by mild acidity. Fertil Steril 2000; 73: 687-693. (Pubitemid 30154104)
30. Rusconi S, Moonis M, Merrill DP et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996; 40: 234-236. (Pubitemid 26020755)
31. Weber J, Nunn A, O'Connor T et al. 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. AIDS 2001; 15: 1563-1568. (Pubitemid 32744604)
32. Pearce-Pratt R & Phillips DM. Sulphated polysaccharides inhibit lymphocyte-to-epithelial transmission of HIV. Biol Reprod 1996; 54: 173-182. (Pubitemid 126506813)
33. Turville SG, Aravantinou M, Miller T et al. Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 2008; 3: e3162.
34. Viread (package insert). Foster City, CA: Gilead Sciences, Inc, 2011.
35. Parikh UM, Dobard C, Sharma S et al. Complete protection from repeated vaginal simian-human deficiency virus exposures in macaques by topical gel containing tenofovir alone or with emtricitabine. J Virol 2009; 83: 10358-10365.
36. *Dobard C, Sharma S, Martin A et al. Durable protection from vaginal SHIV infection in macaques by tenofovir gel and its relationship to tissue drug levels. J Virol 2012; 86: 718-725.
37. Cranage M, Sharpe S, Herrera C et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 2008; 5: e157.
38. Nuttall J, Kashuba A, Wang R et al. Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob Agents Chemother 2012; 56: 103-109.
39. Denton PW, Othieno F, Martinez-Torres F et al. Topically applied 1% tenofovir in humanized BLT mice using the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection validating the BLT model for the evaluation of new microbicide candidates. J Virol 2011; 85: 7582-7593.
40. *Schwartz J, Rountree W, Kashuba ADM et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 2011; 6: e25974.
41. Hoetelmans RMW, Marien K, De Pauw M et al. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br J Clin Pharmacol 2007; 64: 655-661. (Pubitemid 47568821)
42. Hendrix C, Minnis A, Guddera V, et al. MTN-001: a phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. 18th Conference on Retroviruses and Opportunistic Infections 27 Feb - 2 Mar 2011. Boston, MA. Paper #35LB.
43. Anton P, Cranston R, Carballo-Diequez A, et al. RMP-02/MTN-006: A phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDF. 18th Conference on Retroviruses and Opportunistic Infections 27 Feb - 2 Mar 2011. Boston, MA. Paper #34LB.
44. Dezzutti CS, Rohan LC, Lynam JD, et al. Tenofovir Gel Reformulation Results in Improved Product Safety for Rectal Application. 18th Conference on Retroviruses and Opportunistic Infections 27 Feb - 2 Mar 2011. Boston, MA. Paper #983.
45. Microbicide Trials Network. MTN-007: Phase I Tenofovir gel rectal safety study; http://www.mtnstopshiv.org/news/studies/mtn007 [accessed 15.01.12].
46. *Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of Tenofovir Gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-1174.
47. Kashuba ADM, Abdool Karim SS, Kraft E, et al. Do systemic and genital tract tenofovir concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trial? XVIII International AIDS Conference. Vienna, Austria pp. 18-23 Jul 2011. Abstract TUSS0502.
48. *Abdool Karim SS, Kashuba ADM, Werner L & Abdool Karim Q. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378: 279-281.
49. Microbicide Trials Network. MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women. Immediate press release 25 Nov 2011; http://www.mtnstopshiv.org/node/3909 [accessed 15.01.12].
50. FACTS Consortium. FACTS 001 study design; http://www.facts-consortium.co. za/ [accessed 15.01.12].
51. Das K, Clark Jr. AD, Lewi PJ et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47: 2550-2560. (Pubitemid 38580092)
52. D'Cruz OJ & Uckun FM. Dawn of non-nucleoside inhibitor based anti-HIV microbicides. J Antimicrob Chemother 2006; 57: 411-423. (Pubitemid 43240192)
53. *Nicol MR & Kashuba ADM. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther 2010; 88: 598-609.
54. Nuttall JP, Thake DC, Lewis MG et al. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapirivine for 7 days. Antimicrob Agents Chemother 2008; 53: 487-495.
55. Nel AM, Coplan P, van de Wijgert JH et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 2009; 23: 1531-1538.
56. Nel AM, Coplan P, Smythe SC et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 2010; 26: 1181-1190.
57. Nel AM, Smythe SC, Habibi S et al. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety Vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 2010; 55: 161-169.
58. International Partnership for Microbicides. IPM Product Pipeline. Silver Spring, MD; http://www.ipmglobal.org/products-development [accessed 15.01.12].
59. Soares EA, Santos AF, Sousa TM et al. Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS One 2007; 2: e730.
60. Schader SM, Colby-Germinario SP, Schachter J et al. Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination. AIDS 2011; 25: 1585-1594.
61. Romano J, Variano B, Coplan P et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009; 25: 483-488.
62. Nel A, Habibi S, Smythe S, et al. Pharmacokinetics and Safety Assessment of Monthly Anti-HIV DPV Vaginal Microbicide Rings with Multiple Dosing. 18th Conference on Retroviruses and Opportunistic Infections. February 27 - March 2, 2011. Paper #1001.
63. Microbicide Trials Network. MTN-013/IPM 026: Phase 1 Safety and Pharmacokinetics of Dapivirine/Maraviroc Intravaginal Ring; http://www. mtnstopshiv.org/studies/2241 [accessed 15.01.12].
64. Selzentry (package insert). Research Triangle Park, NC: ViiV Healthcare, 2010.
65. ClinicalTrials.gov. A safety and pharmacokinetic study for dapvirine and maraviroc gel in Belgium. ClinicalTrials.gov Identifier: NCT01242579; http://clinicaltrials.gov/ct2/show/NCT01242579 [accessed 15.01.12].
66. *Friend DR & Doncel GF. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: development of dual-protection technologies. Antiviral Res 2010; 885: s47-s54.
67. Cole AM, Hong T, Boo LM et al. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A 2002; 99: 1813-1818. (Pubitemid 34168972)
68. Cole AM, Patton DL, Rohan LC et al. The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One 2010; 5: e15111.
69. Sassi AB, Cost MR, Cole AL et al. Formulation development of retrocyclin 1 analog RC-101 as an anti-HIV vaginal microbicide product. Antimicrob Agents Chemother 2011; 55: 2282-2289.
70. *Kashuba ADM, Patterson KB, Dumond JB et al. Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet 2011. epub ahead of print.